AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Personalis shares surge 11.71% intraday as NeXT Personal® breast cancer tests gain Medicare coverage, with Q4 2025 preliminary data set for January 8, 2026.
ByAinvest
Thursday, Jan 22, 2026 10:38 am ET1min read
PSNL--
Personalis surged 11.71% intraday trading, driven by Medicare coverage for its NeXT Personal breast cancer tests, effective retroactively from October 7, 2025, with reimbursements of $3,878 for the NeXT Personal Dx Breast MRD test and $1,158 for the Single Plasma test. The company also announced plans to release preliminary Q4 2025 financial and operational data on January 8, 2026.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc's editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet